SAN FRANCISCO, May 12, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the ...

Revenue: US$3.03m (down 95% from 1Q 2024). Net loss: US$121.0m (loss widened by 85% from 1Q 2024). US$0.88 loss per share (further deteriorated from US$0.48 loss in 1Q 2024). We've found 21 US ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Dr Rajesh Gupta, vice president, global health portfolio and public-private partnerships at Vir Biotechnology, said: “COVID-19 reinforced the ever-present global threat of infectious diseases ...

With over 30 years of experience in drug development, Dr. Korman has shaped groundbreaking advancements in the field, most recently serving as an executive at Vir Biotechnology and Bristol Myers ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the ...